An open-label, non-randomized study to evaluate the effect of tesaglitazar 1 mg once daily doses on ovulation suppression in healthy female volunteers on an combined oral contraceptive containing drospirenone and ethinyl estradiol

Study identifier:D6160C00057

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open-label, non-randomized study to evaluate the effect of tesaglitazar 1 mg once daily doses on ovulation suppression in healthy female volunteers on an combined oral contraceptive containing drospirenone and ethinyl estradiol

Medical condition

Diabetes Mellitus

Phase

Phase 1

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Feb 2006
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria